TRANSFUSION OF BLOOD COMPONENTS ADMINISTRATION. All blood components are administered according to BOP DHB Policy and NZBS Guidelines.

Similar documents
Chapter 8 ADMINISTRATION OF BLOOD COMPONENTS

Components of Blood. N26 Blood Administration 4/24/2012. Cabrillo College ADN/C. Madsen RN, MSN 1. Formed elements Cells. Plasma. What can we give?

To provide guidelines for the identification, management and reporting of a suspected transfusion reaction to Transfusion Medicine Laboratory (TML).

TRANSFUSION SAFETY 101 ARE YOU SMARTER THAN A BLOOD BANKER?

Unit 5: Blood Transfusion

Blood/Blood Component Utilization and Administration Annual Compliance Education

Blood & Blood Product Administration

Policy for the safe handling and administration of cytotoxic drugs for Children, Teenagers and Young Adults with Cancer

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY

Definitions of Current SHOT Categories & What to Report

GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION

IV Fluids. Nursing B23. Objectives. Serum Osmolality

2/2/2011. Blood Components and Transfusions. Why Blood Transfusion?

BPG 03: Continuous Renal Replacement Therapy (CRRT)

MB Guideline 7. Transfusion Reaction- Identification, Management and Reporting

INTRAVENOUS HYDRALAZINE POLICY

CENTRAL VENOUS ACCESS DEVICES. BETHANY COLTON

PHARMACOLOGY AND PHARMACOKINETICS

Essential Transfusion. Medical Students

Blood Transfusion. Dr Will Dooley

SARASOTA MEMORIAL HOSPITAL

Transfusion Reactions

Revised November 2012

IV Fluids Nursing B23 Objectives Serum Osmolality 275 to 295 Isotonic

4 PARENTERAL THERAPY

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS NLBCP-006. Issuing Authority

A step-by-step preparation guide

Have you ever managed patients who have experienced an adverse reaction to transfusion?

CATHETER ACCESS KIT. For use with Prometra Programmable Infusion Systems

Infusion of intravenous gamma globulin (immunoglobulins)

Package Leaflet: Information for the user. NAVELBINE 10 mg/ml concentrate for solution for infusion Vinorelbine (as tartrate)

PATIENT CARE PLAN FOR CARE OF PERIPHERAL MIDLINE. Manufacturers specific recommendations should be noted and adhered to by individual practitioners.

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

FLUID MANAGEMENT AND BLOOD COMPONENT THERAPY

Administration of blood components. Tina Parker - Transfusion Practitioner

This guideline describes the care required for a patient receiving a red blood cell transfusion whilst undergoing extra corporeal therapies.

Presentation Created by; Shana Chiborak RN CNCC (C) Nurse Coordinator Blood Management Service May 2016

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid

Fundamentals of Flushing and Locking

Clinical guideline: manual red cell exchange in patients with sickle cell disease

SUMMARY OF PRODUCT CHARACTERISTICS. Flexbumin 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.

Cardiac Catheter Labs Intravenous Drug Therapy Guide

TRANSFUSION REACTION EVALUATION

Curraheen, Co. Cork. Guidelines on the Management and Care of Central Venous Access Devices

VAN WERT COUNTY HOSPITAL. Policy/Procedure: Departmental No.: N 11-36A. Issue Date: 7-97 By: Nursing No. of Pages: 6

Education for Self Administration of Intravenous Therapy HOME IV THERAPY PICC. Portacath

DRUG GUIDELINE SODIUM NITROPRUSSIDE

Emergency clamp should always be readily available in case of accidental catheter fracture

Albumex 4 NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY CLINICAL TRIALS. New Zealand Data Sheet. Human Albumin 4% (40 g/l)

Package leaflet: Information for the user

(galsulfase) DOSING & ADMINISTRATION GUIDE

ATI Skills Modules Checklist for Central Venous Access Devices

DRUG GUIDELINE. HYDRALAZINE (Intravenous severe hypertension in pregnancy)

Neonatal Parenteral Nutrition Guideline Dr M Hogan, Maire Cullen ANNP, Una Toland Ward Manager, Sandra Kilpatrick Neonatal Pharmacist

If viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.

PRODUCT INFORMATION. NAME OF THE MEDICINE Compound Sodium Lactate (Hartmann's) Solution for Injection

Complications Associated With IV Therapy

Clinical Competency Name: Post-operative use of Metaraminol in Recovery

Oxytocin APOTEX Solution for Injection Contains the active ingredient synthetic oxytocin

ACETYLCYSTEINE INJECTION

Pharmacy Instructions for Preparation

Management of an immediate adverse event following immunisation

Intravenous therapy and medication. ELCT Health Department Quality Assurance 2007

Saline (0.9%) Nebuliser Guideline

IV Link Staff. Infection Prevention & Control A Learning Package for IV Link Staff

All institutions that transfuse blood components and products should implement national and local policies and written procedures for:

0.45% Sodium Chloride Injection, USP

Slide 1. Slide 2. Slide 3. What is injection safety Safe injection practices- Blood glucose monitoring Sharp safety.

Optimal nutrition in critically ill children

Transfusion Reactions. Directed by M-azad March 2012

EVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11

Blood Transfusion. Dr William Dooley

belimumab (rmc) 120 mg and 400 mg powder Please read this leaflet carefully before you are given BENLYSTA.

F: Respiratory Care. College of Licensed Practical Nurses of Alberta, Competency Profile for LPNs, 3rd Ed. 59

H: Respiratory Care. Saskatchewan Association of Licensed Practical Nurses, Competency Profile for LPNs, 3rd Ed. 79

CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)

Blood Bank Instructions

Guidelines for the Care and Maintenance of Intravenous Access Devices in Paediatric Patients

Midazolam Injection Midazolam

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Product Information BROWN SNAKE ANTIVENOM AUST R 74897

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

Overview of CVADs. Type of device commonly used. Dwell time Flushing requirement Associated complications. lumens

Prof A Pourazar Immunohematologist

Package leaflet: Information for the user. Cyanokit 5 g powder for solution for infusion hydroxocobalamin

CONTROLLED DOCUMENT. Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) Controlled Document Number: CG259

DR J HARTY / DR CM RITCHIE / DR M GIBBONS

Human Albumin 200 g/l Baxter is a solution containing 200 g/l of total protein of which at least 95% is human albumin.

Package leaflet: Information for the user. SmofKabiven emulsion for infusion

Department Policy. Code: D:PC Entity: Fairview Pharmacy Services. Department: Fairview Home Infusion. Manual: Policy and Procedure Manual

Education for self administration of intravenous therapy HOME IV THERAPY. 30 minute - Baxter Pump Tobramycin

Blood Transfusion Reactions

PAEDIATRIC NERVE BLOCK / WOUND INFILTRATION

Paravertebral policy. The Acute pain Management Dept, UCLH

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests

Before you are given CYRAMZA. When you must not be given it

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

NEXIUM INTRAVENOUS esomeprazole sodium

Transcription:

STANDARDS All blood components are administered according to BOP DHB Policy and NZBS Guidelines. EQUIPMENT IV administration set with 260 micron filter either integrated blood filter; or add on blood filter Non-sterile gloves Alcohol swab Blood warmer may be required for rapid transfusion (>200ml/hr); or if advised by Transfusion Laboratory. Pressure bags may be used for the rapid administration of blood components during resuscitation or intraoperative management. They must not be used routinely for administration of blood products due to danger of extravasation. Volumetric infusion pumps (both Flogard and Colleague) - may be used for blood product administration however extra vigilance of status of infusion site is required. 1 2 Prior to collection of blood products from the Transfusion Laboratory - assess individual patient s venous access to identify any patency issues Ensure that the patient has patent IV cannula - recommended minimum size for adult patients is 20g, paediatric patients - 22-24g. Blood may be administered via a PICC or CV access device however some small tubing diameters may pose problems with blood or platelet transfusion leading to slow flow rates and clogging. Blood product administration must be completed within 4 hours of issue from the Transfusion Laboratory / Blood Bank. IF product can not be immediately transfused it must be returned to the Transfusion laboratory within 30 minutes if it is to be reissued. Blood products must never be stored within the clinical area in anything other than the small transportation cooler bins supplied by the Transfusion Laboratory. Administration of blood products stored within these transportation bins must commence within 60 minutes of dispensing of product from the Transfusion Laboratory. To reduce delays in commencement of administration once blood issued. To meet NZ Blood Service standards for safe management of transfusion components. Page 1 of 6

3 Checking of blood components and patient identity The checking process must include: - Verifying that the patient has consented to administration and that the blood component has been ordered correctly. Patient ID wristband (and verbal identification of patient whenever possible) - with corresponding NHI number on prescription and transfusion orders and label on the blood product. Blood product unit number on bag/ bag label and Blood Product Transfusion Request form. Details of the patient s blood group and Rh against label on Blood Product Bag and product issued. Time that the product left the Transfusion Laboratory and the appearance of product / container integrity. Expiry date of the product. If in doubt about compatibility contact the Transfusion Laboratory. The component (particularly red cells) should be mixed thoroughly by gentle inversion before use. Always use gloves when handling blood components. To avoid the significant risk to patient safety if incorrect component is administered. To ensure blood component meets safe quality standards. To prevent contamination 4 Monitoring of Patient Transfusion reactions are Record patient baseline pulse rate, blood most likely to occur within pressure, temperature, respiratory rate and 15 minutes of general condition immediately prior to commencement of commencing transfusion. administration therefore On commencement of transfusion patient must extra precautions must be be monitored closely for any signs of adverse taken to observe patients reaction: during this time. (a) Baseline observations must be repeated after 15 minutes. (b) Patient must be able to contact nursing staff at all times, if this is not possible, e.g. the patient is unconscious, then the person responsible for administration must stay with the patient for the first 15 minutes of each unit. (c) Patient is assessed every 30 minutes during blood administration. This assessment includes pulse, respiratory rate, and Page 2 of 6

5 observations for signs of adverse reaction, e.g. urticaria, pruritis, rash, rigors, chills, hypotension, nausea, vomiting, chest pain, oliguria, flank pain, headache, wheezing, laryngeal oedema; or fluid overload e.g. dyspnoea, tachycardia, respiratory failure, hypoxia, cyanosis. Temperature and blood pressure is assessed hourly. Administration: All products derived from human blood product must be administered using a blood filter. Transfusion Laboratory will notify the clinical area if a blood warmer is required for product administration. IV administration sets are changed after every second unit and following the administration of last prescribed transfusion in patient s orders for the day. Administration sets should be flushed with 0.9 % Sodium Chloride prior to commencing and after completion of blood transfusion. In emergency / theatre situations - 8-10 units may be transfused before the set is changed. For transfusion during prolonged resuscitation (e.g. in theatre) the set must be changed every 8 hours or as soon as last unit of red cells administered. Platelets must not be administered via a line used for red cell administration. Blood products should be administered via a peripheral line when at all possible. If this is not possible, and a central line is used for blood product administration - use an electronic pump to ensure steady infusion rate and flush the line with 20 mls 0.9% Normal Saline after transfusion to reduce risk occlusion to central line. Medication or other additives (other than 0.9% Sodium Chloride or 4% Albumin solution) must never be added to blood products and the use of the blood administration line for medication administration should be avoided when ever possible. In the event of no other access being available the blood product administration must be stopped and the line flushed with 20mls of 0.9% Sodium Chloride before and after To reduce risk of bacterial contamination Blood components may be incompatible with intravenous solutions (e.g. Glucose). To avoid delays to infusion Red cells in the filter may cause platelets to aggregate. To avoid incompatibility issues. Page 3 of 6

6 7 medication administration. Blood products may be administered using Electronic Volumetric Infusion pumps Floguard and Colleague, available at both Tauranga and Whakatane Hospitals, using an in-line blood filter and standard IV set (compatible with pump selected). Completion or interruption of transfusion Transfusion of blood products must be completed within 4 hours of issuing from the Transfusion Laboratory. If the transfusion is interrupted, for example if IV cannula requires resiting during the transfusion: (a) Assess reason for cannula resiting if any sign of infection in current site discard giving set and blood product (b) If the cannula can be resited immediately (within 5-10 minutes) and you are certain that the giving set has not been contaminated during disconnection you may recommence transfusion using existing administration set. (c) If there is a delay (greater than 15 minutes) in resiting cannula or you suspect that the giving set may have been contaminated (e.g. accidental dislodgment of cannula) replace the giving set using aseptic technique and recommence transfusion within one hour of stopping administration provided transfusion can then be completed within four hours of the product having been dispensed from the Transfusion Laboratory. Adverse reaction to Transfusion Adverse reactions to blood products are potentially emergency situations. Stop transfusion; assess Airway, Breathing and Circulation; call for emergency assistance if necessary. In the event of the patient experiencing an adverse reaction to any blood product the clinical staff must notify the Transfusion Laboratory immediately. A Transfusion Reaction Investigation Form will be sent from the Transfusion Laboratory and must be completed by the medical staff responding to the reaction - and returned with relevant samples as requested to the Transfusion Laboratory. To avoid administration of potentially contaminated blood component; or a unit that has been out of monitored storage for longer than recommended time period of 4 hours. Page 4 of 6

Reaction must also be fully documented in patient s clinical notes. 8 Documentation and disposal of completed transfusion bags The product / patient identification label off the blood product must be entered into patients clinical notes on completion of administration. (a) At Tauranga this is placed onto the back of Blood Product request form in the patient s clinical record. (b) At Whakatane this is placed in the patient s clinical record. On completion of transfusion remove administration set and filter, place empty transfusion bag in sealed Biohazard bag and return immediately to the Transfusion Laboratory. Transfusion Laboratory store used bags for follow up in the incidence of delayed transfusion reaction. REFERENCES Australian and New Zealand Society of Blood Transfusion Inc. Royal College of Nursing Australia, 2004. Guidelines for the Administration of Blood Components. (1 st Ed.) Mallet J. and Dougherty L. Manual of Clinical Nursing Procedures, The Royal Marsden Hospital, 5 th Edition (Internet): Available BOP DHB Intranet Nursing site. Page 5 of 6

Intentionally blank page Page 6 of 6